Literature DB >> 23996116

MRI differentiation of cardiomyopathy showing left ventricular hypertrophy and heart failure: differentiation between cardiac amyloidosis, hypertrophic cardiomyopathy, and hypertensive heart disease.

Minako Takeda1, Yasuo Amano, Masaki Tachi, Hitomi Tani, Kyoichi Mizuno, Shinichiro Kumita.   

Abstract

PURPOSE: To evaluate the capability of MRI to differentiate cardiac amyloidosis (CA), end-stage hypertrophic cardiomyopathy (HCM), and hypertensive heart disease (HHD), which are important etiologies of left ventricular hypertrophy (LVH) and heart failure.
MATERIALS AND METHODS: We enrolled 26 patients presenting with both LVH and heart failure: six with CA, nine with end-stage HCM, and 11 with HHD. Cardiac function, presence of pericardial or pleural effusion, and the extent and patterns of late gadolinium enhancement (LGE) were compared among the three diseases.
RESULTS: Myocardial LGE was observed in all six CA patients, eight end-stage HCM patients, and six HHD patients. The number of LGE segments was significantly greater in CA than in HCM or HHD (p = 0.02 for both), and all patients with CA showed a global endocardial pattern of LGE. There were significant differences among CA, HCM, and HHD in ejection fraction and end-diastolic and end-systolic volume indices (p < 0.05 for all). Pericardial effusion was observed more frequently in CA than in HCM or HHD (p = 0.04 or 0.01, respectively).
CONCLUSION: MRI is valuable for distinguishing among CA, end-stage HCM, and HHD, all of which present with LVH and heart failure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23996116     DOI: 10.1007/s11604-013-0238-0

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  29 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy.

Authors:  Martin S Maron; Evan Appelbaum; Caitlin J Harrigan; Jacki Buros; C Michael Gibson; Connie Hanna; John R Lesser; James E Udelson; Warren J Manning; Barry J Maron
Journal:  Circ Heart Fail       Date:  2008-06-23       Impact factor: 8.790

3.  Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy.

Authors:  R Fattori; G Rocchi; F Celletti; P Bertaccini; C Rapezzi; G Gavelli
Journal:  Am Heart J       Date:  1998-11       Impact factor: 4.749

4.  Prevalence of systolic impairment in an unselected regional population with hypertrophic cardiomyopathy.

Authors:  Georgios K Efthimiadis; Georgios Giannakoulas; Despina G Parharidou; Haralampos I Karvounis; Soterios T Mochlas; Ioannis H Styliadis; Stavros Gavrielides; Konstantinos D Gemitzis; Georgios D Giannoglou; Georgios E Parharidis; Georgios E Louridas
Journal:  Am J Cardiol       Date:  2006-09-18       Impact factor: 2.778

5.  Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance.

Authors:  E Perugini; C Rapezzi; T Piva; O Leone; L Bacchi-Reggiani; L Riva; F Salvi; L Lovato; A Branzi; R Fattori
Journal:  Heart       Date:  2005-06-06       Impact factor: 5.994

6.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

7.  Cardiovascular magnetic resonance in cardiac amyloidosis.

Authors:  Alicia Maria Maceira; Jayshree Joshi; Sanjay Kumar Prasad; James Charles Moon; Enrica Perugini; Idris Harding; Mary Noelle Sheppard; Philip Alexander Poole-Wilson; Philip Nigel Hawkins; Dudley John Pennell
Journal:  Circulation       Date:  2005-01-03       Impact factor: 29.690

8.  MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis.

Authors:  Waldemar Hosch; Michael Bock; Martin Libicher; Sebastian Ley; Ute Hegenbart; Thomas J Dengler; Hugo A Katus; Hans-Ulrich Kauczor; Günter W Kauffmann; Arnt V Kristen
Journal:  Invest Radiol       Date:  2007-09       Impact factor: 6.016

Review 9.  Hypertrophic cardiomyopathy.

Authors:  Perry Elliott; William J McKenna
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

Review 10.  Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy.

Authors:  Martin S Maron
Journal:  J Cardiovasc Magn Reson       Date:  2012-02-01       Impact factor: 5.364

View more
  7 in total

Review 1.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

2.  Severe Left Ventricular Hypertrophy, Small Pericardial Effusion, and Diffuse Late Gadolinium Enhancement by Cardiac Magnetic Resonance Suspecting Cardiac Amyloidosis: Endomyocardial Biopsy Reveals an Unexpected Diagnosis.

Authors:  Nina P Hofmann; Sorin Giusca; Karin Klingel; Peter Nunninger; Grigorios Korosoglou
Journal:  Case Rep Cardiol       Date:  2016-05-10

3.  Senile Systemic Amyloidosis Presenting as Hematuria: A Rare Presentation and Review of Literature.

Authors:  Thejus Jayakrishnan; Amir Kamran; Deep Shah; Aritra Guha; Muhammad Salman Faisal; Prerna Mewawalla
Journal:  Case Rep Med       Date:  2020-01-03

Review 4.  Anatomical-MRI Correlations in Adults and Children with Hypertrophic Cardiomyopathy.

Authors:  Radu Ovidiu Rosu; Ana Lupsor; Alexandru Necula; Gabriel Cismaru; Simona Sorana Cainap; Daniela Iacob; Cecilia Lazea; Andrei Cismaru; Alina Gabriela Negru; Dana Pop; Gabriel Gusetu
Journal:  Diagnostics (Basel)       Date:  2022-02-14

5.  Fast 3-Breath-Hold 3-Dimensional Tagging Cardiac Magnetic Resonance in Patients with Hypertrophic Myocardial Diseases: A Feasibility Study.

Authors:  Yasuo Amano; Fumi Yamada; Hidenobu Hashimoto; Makoto Obara; Kuniya Asai; Shinichiro Kumita
Journal:  Biomed Res Int       Date:  2016-02-28       Impact factor: 3.411

6.  Cardiac MR Imaging of Hypertrophic Cardiomyopathy: Techniques, Findings, and Clinical Relevance.

Authors:  Yasuo Amano; Mitsunobu Kitamura; Hitoshi Takano; Fumi Yanagisawa; Masaki Tachi; Yasuyuki Suzuki; Shinichiro Kumita; Morimasa Takayama
Journal:  Magn Reson Med Sci       Date:  2018-01-18       Impact factor: 2.471

7.  Autonomic dysfunction in cardiac amyloidosis assessed by heart rate variability and heart rate turbulence.

Authors:  Shinya Yamada; Akiomi Yoshihisa; Naoko Hijioka; Masashi Kamioka; Takashi Kaneshiro; Tetsuro Yokokawa; Tomofumi Misaka; Takafumi Ishida; Yasuchika Takeishi
Journal:  Ann Noninvasive Electrocardiol       Date:  2020-02-21       Impact factor: 1.468

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.